Devaraja K, Aggarwal Sadhna, Singh Manisha
Division of Head and Neck Surgery, Department of ORL-HNS, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Udupi 576104, Karnataka, India.
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Vaccines (Basel). 2023 Mar 13;11(3):634. doi: 10.3390/vaccines11030634.
Therapeutic vaccination is one of the most effective immunotherapeutic approaches, second only to immune checkpoint inhibitors (ICIs), which have already been approved for clinical use. s are heterogenous epithelial tumors of the upper aerodigestive tract, and a significant proportion of these tumors tend to exhibit unfavorable therapeutic responses to the existing treatment options. Comprehending the immunopathology of these tumors and choosing an appropriate immunotherapeutic maneuver seems to be a promising avenue for solving this problem. The current review provides a detailed overview of the strategies, targets, and candidates for therapeutic vaccination in HNSCC. The classical principle of inducing a potent, targeting a specific seems to be the most effective mechanism of therapeutic vaccination, particularly against the subset of HNSCC. However, approaches such as of HNSCC and have also been explored recently, with encouraging results.
治疗性疫苗接种是最有效的免疫治疗方法之一，仅次于已被批准用于临床的免疫检查点抑制剂（ICI）。头颈部鳞状细胞癌（HNSCC）是上消化道的异质性上皮肿瘤，这些肿瘤中有很大一部分对现有治疗方案往往表现出不利的治疗反应。了解这些肿瘤的免疫病理学并选择合适的免疫治疗策略似乎是解决这一问题的一个有前景的途径。本综述详细概述了HNSCC治疗性疫苗接种的策略、靶点和候选疫苗。诱导强效免疫反应、靶向特定抗原的经典原则似乎是治疗性疫苗接种最有效的机制，尤其是针对HNSCC的特定亚群。然而，最近也探索了诸如HNSCC的过继性细胞免疫治疗和溶瘤病毒疗法等方法，并取得了令人鼓舞的结果。
